(3S)-3-[4-(dimethylamino)phenyl]-2-prop-2-ynyl-9-oxa-2-azaspiro[5.5]undecan-1-one | 1189570-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: (3S)-3-[4-(dimethylamino)phenyl]-2-prop-2-ynyl-9-oxa-2-azaspiro[5.5]undecan-1-one
• CAS: 1189570-26-0
• 化学式: C₂₀H₂₆N₂O₂
• 分子量: 326.439
• InChiKey: WKCKDSYFNMUQSA-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Selnick Harold G.

  公开号：US20110021516A1

  公开（公告）日：2011-01-27

  The present invention is directed to compounds of the formula (I): (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , G 1 , G 2 , G 3 , G 4 , J, Q, E a , E b , E c , R 6 , R 7 , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式(I)的化合物：（其中变量A1、A2、A3、A4、A5、A6、A7、A8、G1、G2、G3、G4、J、Q、Ea、Eb、Ec、R6、R7、RPG和Y如本文所述），它们是CGRP受体拮抗剂，并且在治疗或预防CGRP参与的疾病，如偏头痛中有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• US8765759B2
  申请人：——

  公开号：US8765759B2

  公开（公告）日：2014-07-01
• [EN] MONOCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS CGRP MONOCYCLIQUES
  申请人：MERCK & CO INC

  公开号：WO2009120652A2

  公开（公告）日：2009-10-01

  The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.